Overview

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sun Pharma Advanced Research Company Limited